Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/22792
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Type: Journal article
Title: Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments
Author: Barratt, D.
Coller, J.
Somogyi, A.
Citation: American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 2006; 141B(4):323-331
Publisher: Wiley-Liss
Issue Date: 2006
ISSN: 1552-4841
1552-485X
Statement of
Responsibility: 
Daniel T. Barratt, Janet K. Coller and Andrew A. Somogyi
Abstract: The TaqI A polymorphism (A(1)) of the dopamine D(2) receptor gene (DRD2), although not a specific predictor of opioid dependence, has been strongly associated with high levels of prior heroin use and poor treatment outcomes among methadone maintenance patients. The aims of this study were to confirm these findings via a retrospective analysis of A(1) allele frequency in methadone (n = 46) and buprenorphine (n = 25) patients, and non-opioid-dependent controls (n = 95). Subjects were genotyped at the DRD2 TaqI A locus using PCR amplification followed by TaqI restriction enzyme digestion and gel electrophoresis. For methadone and buprenorphine subjects, heroin use (prior to treatment), treatment outcomes, and withdrawal occurrence were determined from comprehensive case notes. No significant differences in A(1) allele frequency (%) were observed between: methadone (19.6%), buprenorphine (18.0%), and control (17.9%) groups (P > 0.7); successful and poor treatment outcome groups, methadone: 20.0% and 19.2%, respectively (P = 1.0); buprenorphine: 18.4% and 20.0%, respectively (P = 1.0). Also, there were no significant relationships between TaqI A genotype and prior heroin use (P = 0.47). However, among the successful methadone subjects, significantly fewer A(1) allele carriers experienced withdrawal than non-A(1) carriers (P = 0.04). In conclusion, the DRD2 genotype effects did not affect opioid maintenance treatment outcomes. This suggests the need for a further prospective investigation into the role of the DRD2 A(1) allele in heroin use and response to maintenance pharmacotherapies for opioid dependence.
Keywords: dopamine receptor; treatment outcome; heroin; opioid dependence
Description: The definitive version is available at www3.interscience.wiley.com.
RMID: 0020060640
DOI: 10.1002/ajmg.b.30319
Published version: http://www3.interscience.wiley.com/cgi-bin/jissue/112634219
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.